Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
TCRT | US
Overview
Corporate Details
- ISIN(s):
- US98973P1012
- LEI:
- Country:
- United States of America
- Address:
- 501 E LAS OLAS BLVD, 33301 FORT LAUDERDALE
- Website:
- https://alaunos.com/
Description
Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company developing T-cell receptor (TCR)-T cell therapies for the treatment of solid tumors. The company's approach targets cancer-specific neoantigens that arise from genomic hotspot mutations. It utilizes its proprietary hunTR® (human neoantigen T cell Receptor) platform as a discovery engine to identify and expand its library of tumor-specific TCRs. For manufacturing its cell therapies, Alaunos employs the *Sleeping Beauty* non-viral gene transfer system, a technology noted for its favorable safety profile and rapid, cost-effective production. The company's mission is to deliver tumor-specific T-cell therapies to cancer patient populations with unmet clinical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alaunos Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alaunos Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alaunos Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
